BioNTech’s €2.75 Billion Revenue Year Ended in Loss — Now the Market Wants to See a Return on Its R&D Billions

Shareholders back management at annual meeting, but BioNTech's stock drops 2.22% amid heavy R&D costs and unproven oncology pivot; analysts see upside at $118-$131.

Shareholders gave BioNTech’s management a clean slate at the company’s annual general meeting on May 15, approving every resolution put to a vote — including the discharge of the executive and supervisory boards. Yet the stock market response was anything but celebratory. The stock closed the week at €76.95, down 2.22% on the day, leaving it roughly 25% below its 52-week high of €101.90. Over the past 30 days, shares have lost around 8%, and the year-to-date decline stands at nearly 7%.

The disconnect between shareholder support and investor sentiment reflects a fundamental challenge: BioNTech is spending heavily to reinvent itself, but the payoff remains largely unproven. For the 2024 fiscal year, the company booked revenue of €2.75 billion alongside a net loss of roughly €665 million — a direct consequence of the massive outlays needed to push a broad oncology pipeline through late-stage trials. Management has confirmed its 2026 revenue target of between €2.0 billion and €2.3 billion, while adjusted research and development costs are expected to land in a range of €2.2 billion to €2.5 billion.

To offset some of that spending pressure, BioNTech has launched a cost-cutting program targeting annual savings of €500 million by 2029 through the consolidation of its production network. An upfront payment of $3.5 billion from the Bristol Myers Squibb partnership provides near-term liquidity, and the company has also authorised a share buyback of up to $1 billion to be executed over the next twelve months.

Analysts, for their part, see a significant gap between the current trading level and where the stock could head if the oncology bet pays off. The average price target among covering analysts stands at $118.44 according to one survey, while a second consensus puts the figure at $131.60 with a “Moderate Buy” rating. Much of that optimism hinges on the lead oncology candidate, Pumitamig (BNT327), for which key data packages are slated for the second half of 2026.

The next scheduled check-in for investors comes on August 4, when BioNTech reports its second-quarter results. The focus will be on the progress of the 15 ongoing Phase 3 trials and whether the cost-saving measures are beginning to narrow the gap between outflows and eventual revenues.

The AGM also reinforced the company’s strategic shift by expanding the supervisory board from six to eight members. Helmut Jeggle took over as chairman, while Dr. Iris Löw-Friedrich and Dr. Susanne Schaffert — both veterans in clinical oncology development and commercialisation — joined the board. The message was unmistakable: BioNTech is putting its COVID-era identity firmly in the rearview mirror. The question the market wants answered is whether the scale of investment will ultimately translate into a new generation of approved therapies — and how long investors will have to wait.